Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: Preparation, in vitro and in vivo studies

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Saremi, Shahrooz ^a,b   Dinarvand, Rassoul ^a,c   Kebriaeezadeh, Abbas ^a,b   Ostad, Seyed Nasser ^a,c   Atyabi, Fatemeh ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b R and D Department   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM NITRATE; CERIUM; CHITOSAN; DOCETAXEL; NANOCARRIER; POLY(METHYL METHACRYLATE); ANTINEOPLASTIC AGENT; NANOCAPSULE; TAXOID; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CHEMICAL COMPOSITION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; MUCOADHESION; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; RAT; SUSTAINED DRUG RELEASE; TIGHT JUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; DIFFUSION; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION; ULTRASTRUCTURE; WISTAR RAT; CACO 2 CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CHITOSAN; DIFFUSION; HUMANS; MALE; METABOLIC CLEARANCE RATE; NANOCAPSULES; POLYMETHYL METHACRYLATE; RATS; RATS, WISTAR; SULFHYDRYL COMPOUNDS; TAXOIDS; TISSUE DISTRIBUTION;

EID: 84881498020     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/150478     Document Type: Article

References (47)

1. Escobar P. F., Rose P. G., Docetaxel in ovarian cancer. Expert Opinion on Pharmacotherapy 2005 6 15 2719 2726 2-s2.0-29244487074 10.1517/14656566.6.15. 2719 (Pubitemid 41824386)
2. Iwao-Koizumi K., Matoba R., Ueno N., Kim S. J., Ando A., Miyoshi Y., Maeda E., Noguchi S., Kato K., Prediction of docetaxel response in human breast cancer by gene expression profiling. Journal of Clinical Oncology 2005 23 3 422 431 2-s2.0-14544268597 10.1200/JCO.2005.09.078 (Pubitemid 46224217)
3. Eiermann W., Docetaxel-maximising outcomes towards cure in early breast cancer. Breast 2006 15 supplement 3 S13 S16 2-s2.0-33947227807 10.1016/S0960-9776(07)70005-X (Pubitemid 46432160)
4. Gelmon K., The taxoids: paclitaxel and docetaxel. The Lancet 1994 344 8932 1267 1272 2-s2.0-0027942353 10.1016/S0140-6736(94)90754-4 (Pubitemid 24334685)
5. Aapro M., The scientific rationale for developing taxoids. Anti-Cancer Drugs 1996 7 2 33 36 2-s2.0-0029813045 (Pubitemid 26275621)
6. Jones S., Head-to-head: docetaxel challenges paclitaxel. European Journal of Cancer 2006 4 4 4 8 2-s2.0-33646174250 10.1016/S1359-6349(06)80002-9
7. Kuppens I. E. L. M., Bosch T. M., Van Maanen M. J., Rosing H., Fitzpatrick A., Beijnen J. H., Schellens J. H. M., Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemotherapy and Pharmacology 2005 55 1 72 78 2-s2.0-11244321887 10.1007/s00280-004-0864-4 (Pubitemid 40064498)
8. Shou M., Martinet M., Korzekwa K. R., Krausz K. W., Gonzalez F. J., Gelboin H. V., Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998 8 5 391 401 2-s2.0-0031716724 10.1097/00008571-199810000-00004 (Pubitemid 28475303)
9. Malingré M. M., Beijnen J. H., Schellens J. H. M., Oral delivery of taxanes. Investigational New Drugs 2001 19 2 155 162 2-s2.0-0035012398 10.1023/A:1010635000879 (Pubitemid 32423720)
10. Van Zuylen L., Verweij J., Sparreboom A., Role of formulation vehicles in taxane pharmacology. Investigational New Drugs 2001 19 2 125 141 2-s2.0-0035003021 10.1023/A:1010618632738 (Pubitemid 32423718)
11. Malingré M. M., Richel D. J., Beijnen J. H., Rosing H., Koopman F. J., Ten Bokkel Huinink T. B. H. W. W., Schot M. E., Schellens J. H. M., Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. Journal of Clinical Oncology 2001 19 4 1160 1166 2-s2.0-0035865162 (Pubitemid 32176294)
12. Malingré M., Schellens J. H. M., Van Tellingen O., Rosing H., Koopman F. J., Duchin K., Ten Bokkel Huinink W. W., Swart M., Beijnen J. H., Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anti-Cancer Drugs 2000 11 10 813 820 2-s2.0-0033634845 10.1097/00001813-200011000-00004
13. Yousefi A., Esmaeili F., Rahimian S., Atyabi F., Dinarvand R., Preparation and in vitro evaluation of a pegylated nano-liposomal formulation containing docetaxel. Scientia Pharmaceutica 2009 77 2 453 464 2-s2.0-67149104309 10.3797/scipharm.0806-08
14. Immordino M. L., Brusa P., Rocco F., Arpicco S., Ceruti M., Cattel L., Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Journal of Controlled Release 2004 100 3 331 346 2-s2.0-9644302465 10.1016/j.jconrel.2004.09.001 (Pubitemid 39572916)
15. Yin Y.-M., Cui F., Mu C., Choi M., Kim J. S., Chung S., Shim C., Kim D., Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. Journal of Controlled Release 2009 140 2 86 94 2-s2.0-70350618790 10.1016/j.jconrel.2009.08.015
16. Gao K., Sun J., Liu K., Liu X., He Z., Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Development and Industrial Pharmacy 2008 34 11 1227 1237 2-s2.0-54349088541 10.1080/03639040802005057
17. Kim J., Kim Y., Kim S., Park J. H., Kim K., Choi K., Chung H., Jeong S. Y., Park R., Kim I., Kwon I. C., Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. Journal of Controlled Release 2006 111 1-2 228 234 2-s2.0-33344466821 10.1016/j.jconrel.2005.12.013 (Pubitemid 43290012)
18. Esmaeili F., Dinarvand R., Ghahremani M. H., Ostad S. N., Esmaily H., Atyabi F., Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles. Anti-Cancer Drugs 2010 21 1 43 52 2-s2.0-74349089413 10.1097/CAD.0b013e328331f934
19. Dong Y., Feng S., Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005 26 30 6068 6076 2-s2.0-20444416355 10.1016/j.biomaterials.2005.03.021 (Pubitemid 40805612)
20. Nassar T., Attili-Qadri S., Harush-Frenkel O., Farber S., Lecht S., Lazarovici P., Benita S., High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Research 2011 71 8 3018 3028 2-s2.0-79954576965 10.1158/0008-5472.CAN-10-3118
21. Chen H., Zheng Y., Tian G., Tian Y., Zeng X., Liu G., Liu K., Li L., Li Z., Mei L., Huang L., Oral delivery of DMAB-modified docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy. Nanoscale Research Letters 2011 6 1 1 10 2-s2.0-79952696986 10.1007/s11671-010-9741-8
22. Lee E., Kim H., Lee I., Jon S., In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. Journal of Controlled Release 2009 140 2 79 85 2-s2.0-70350622459 10.1016/j.jconrel.2009.08.014
23. Esmaeili F., Dinarvand R., Ghahremani M. H., Amini M., Rouhani H., Sepehri N., Ostad S. N., Atyabi F., Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. Journal of Pharmaceutical Sciences 2009 98 8 2718 2730 2-s2.0-68249129865 10.1002/jps.21599
24. Florence A. T., Hillery A. M., Hussain N., Jani P. U., Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. Journal of Controlled Release 1995 36 1-2 39 46 2-s2.0-0029092672 10.1016/0168-3659(95)00059-H
25. Lin Y. H., Chen C., Liang H., Kulkarni A. R., Lee P., Chen C., Sung H., Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology 2007 18 10 2-s2.0-33947530087 10.1088/0957-4484/18/10/105102 105102 (Pubitemid 46472243)
26. Peltier S., Oger J., Lagarce F., Couet W., Benoît J., Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharmaceutical Research 2006 23 6 1243 1250 2-s2.0-33745386420 10.1007/s11095-006-0022-2 (Pubitemid 43946146)
27. Agüeros M., Zabaleta V., Espuelas S., Campanero M. A., Irache J. M., Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. Journal of Controlled Release 2010 145 1 2 8 2-s2.0-77953360626 10.1016/j.jconrel.2010. 03.012
28. Roldo M., Hornof M., Caliceti P., Bernkop-Schnürch A., Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. European Journal of Pharmaceutics and Biopharmaceutics 2004 57 1 115 121 2-s2.0-0347985635 10.1016/S0939-6411(03)00157-7 (Pubitemid 38058810)
29. Leitner V. M., Guggi D., Krauland A. H., Bernkop-Schnärch A., Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. Journal of Controlled Release 2004 100 1 87 95 2-s2.0-7444254865 10.1016/j.jconrel.2004.08.001 (Pubitemid 39445988)
30. Atyabi F., Moghaddam F. A., Dinarvand R., Zohuriaan-Mehr M. J., Ponchel G., Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: synthesis and characterization. Carbohydrate Polymers 2008 74 1 59 67 2-s2.0-44949187597 10.1016/j.carbpol.2008.01.015
31. Hombach J., Hoyer H., Bernkop-Schnürch A., Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system. European Journal of Pharmaceutical Sciences 2008 33 1 1 8 2-s2.0-36849001337 10.1016/j.ejps.2007.09.001 (Pubitemid 350235186)
32. Moghaddam F. A., Atyabi F., Dinarvand R., Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine 2009 5 2 208 215 2-s2.0-67349238210 10.1016/j.nano.2008.09.006
33. Atyabi F., Talaie F., Dinarvand R., Thiolated Chitosan nanoparticles as an oral delivery system for amikacin: in vitro and ex vivo evaluations. Journal of Nanoscience and Nanotechnology 2009 9 8 4593 4603 2-s2.0-70350362951 10.1166/jnn.2009.1090
34. Saremi S., Atyabi F., Akhlaghi S. P., Ostad S. N., Dinarvand R., Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. International Journal of Nanomedicine 2011 6 1 119 128 2-s2.0-79251511860 10.2147/IJN.S15500
35. Akhlaghi S. P., Saremi S., Ostad S. N., Dinarvand R., Atyabi F., Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine 2010 6 5 689 697 2-s2.0-77957155414 10.1016/j.nano.2010.01.011
36. Saremi S., Atyabi F., Akhlaghi S. P., Ostad S. N., Dinarvand R., Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. International Journal of Nanomedicine 2011 6 1 119 128 2-s2.0-79251511860 10.2147/IJN.S15500
37. Chauvierre C., Labarre D., Couvreur P., Vauthier C., Radical emulsion polymerization of alkylcyanoacrylates initiated by the redox system dextran-cerium(IV) under acidic aqueous conditions. Macromolecules 2003 36 16 6018 6027 2-s2.0-0042475667 10.1021/ma034097w
38. Arangoa M. A., Ponchel G., Orecchioni A. M., Renedo M. J., Duchêne D., Irache J. M., Bioadhesive potential of gliadin nanoparticulate systems. European Journal of Pharmaceutical Sciences 2000 11 4 333 341 2-s2.0-0033805197 10.1016/S0928-0987(00)00121-4
39. Bernkop-Schnürch A., Hornof M., Zoidl T., Thiolated polymers-thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. International Journal of Pharmaceutics 2003 260 2 229 237 2-s2.0-0038460837 10.1016/S0378-5173(03)00271-0 (Pubitemid 36773920)
40. Sadeghi A., Dorkoosh F. A., Avadi M. R., Weinhold M., Bayat A., Delie F., Gurny R., Larijani B., Rafiee-Tehrani M., Junginger H. E., Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics 2008 70 1 270 278 2-s2.0-50249129610 10.1016/j.ejpb.2008.03.004
41. Bravo-Osuna I., Ponchel G., Vauthier C., Tuning of shell and core characteristics of chitosan-decorated acrylic nanoparticles. European Journal of Pharmaceutical Sciences 2007 30 2 143 154 2-s2.0-33846452585 10.1016/j.ejps.2006.10.007 (Pubitemid 46149279)
42. Chen F., Zhang Z., Yuan F., Qin X., Wang M., Huang Y., In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. International Journal of Pharmaceutics 2008 349 1-2 226 233 2-s2.0-37349041646 10.1016/j.ijpharm.2007.07.035 (Pubitemid 350299699)
43. Ma Z., Lim L., Uptake of Chitosan and associated insulin in caco-2 cell monolayers: a comparison between Chitosan molecules and Chitosan nanoparticles. Pharmaceutical Research 2003 20 11 1812 1819 2-s2.0-0344946091 10.1023/B:PHAM.0000003379.76417.3e (Pubitemid 37449455)
44. Artursson P., Lindmark T., Davis S. S., Illum L., Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharmaceutical Research 1994 11 9 1358 1361 2-s2.0-0028071051 10.1023/A:1018967116988 (Pubitemid 24287420)
45. Smith J., Wood E., Dornish M., Effect of Chitosan on epithelial cell tight junctions. Pharmaceutical Research 2004 21 1 43 49 2-s2.0-1642579659 10.1023/B:PHAM.0000012150.60180.e3 (Pubitemid 38122290)
46. Anderberg E. K., Nystrom C., Artursson P., Epithelial transport of drugs in cell culture. VII: effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. Journal of Pharmaceutical Sciences 1992 81 9 879 887 2-s2.0-0027098054 10.1002/jps.2600810908 (Pubitemid 23006838)
47. Dong Y., Feng S., Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005 26 30 6068 6076 2-s2.0-20444416355 10.1016/j.biomaterials.2005.03.021 (Pubitemid 40805612)